Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma.

Davis LE, Bolejack V, Ryan CW, Ganjoo KN, Loggers ET, Chawla S, Agulnik M, Livingston MB, Reed D, Keedy V, Rushing D, Okuno S, Reinke DK, Riedel RF, Attia S, Mascarenhas L, Maki RG.

J Clin Oncol. 2019 Jun 1;37(16):1424-1431. doi: 10.1200/JCO.18.02374. Epub 2019 Apr 23.

PMID:
31013172
2.

Anti-angiogenic therapy for malignant solitary fibrous tumour: validation through collaboration.

Riedel RF.

Lancet Oncol. 2019 Jan;20(1):14-15. doi: 10.1016/S1470-2045(18)30745-9. Epub 2018 Dec 18. No abstract available.

PMID:
30578024
3.

Sorafenib for Advanced and Refractory Desmoid Tumors.

Gounder MM, Mahoney MR, Van Tine BA, Ravi V, Attia S, Deshpande HA, Gupta AA, Milhem MM, Conry RM, Movva S, Pishvaian MJ, Riedel RF, Sabagh T, Tap WD, Horvat N, Basch E, Schwartz LH, Maki RG, Agaram NP, Lefkowitz RA, Mazaheri Y, Yamashita R, Wright JJ, Dueck AC, Schwartz GK.

N Engl J Med. 2018 Dec 20;379(25):2417-2428. doi: 10.1056/NEJMoa1805052.

4.

Assessing the Impact of a Novel Integrated Palliative Care and Medical Oncology Inpatient Service on Health Care Utilization before Hospice Enrollment.

Ray EM, Riedel RF, LeBlanc TW, Rushing CN, Galanos AN.

J Palliat Med. 2019 Apr;22(4):420-423. doi: 10.1089/jpm.2018.0235. Epub 2018 Nov 3.

PMID:
30394821
5.

Systemic Anti-Cancer Therapy in Synovial Sarcoma: A Systematic Review.

Riedel RF, Jones RL, Italiano A, Bohac C, Thompson JC, Mueller K, Khan Z, Pollack SM, Van Tine BA.

Cancers (Basel). 2018 Nov 1;10(11). pii: E417. doi: 10.3390/cancers10110417. Review.

6.

The experiences of older caregivers of cancer patients following hospital discharge.

Schwartz AJ, Riedel RF, LeBlanc TW, Desai D, Jenkins C, Mahoney E, Humphreys J, Hendrix CC.

Support Care Cancer. 2019 Feb;27(2):609-616. doi: 10.1007/s00520-018-4355-2. Epub 2018 Jul 19.

7.

Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Ganjoo KN, George S, Gonzalez RJ, Heslin MJ, Kane JM, Keedy V, Kim E, Koon H, Mayerson J, McCarter M, McGarry SV, Meyer C, Morris ZS, O'Donnell RJ, Pappo AS, Paz IB, Petersen IA, Pfeifer JD, Riedel RF, Ruo B, Schuetze S, Tap WD, Wayne JD, Bergman MA, Scavone JL.

J Natl Compr Canc Netw. 2018 May;16(5):536-563. doi: 10.6004/jnccn.2018.0025.

PMID:
29752328
8.

Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma.

Wisdom AJ, Mowery YM, Riedel RF, Kirsch DG.

Cancer. 2018 Oct 1;124(19):3819-3829. doi: 10.1002/cncr.31517. Epub 2018 May 3. Review.

9.

A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer.

Vlahovic G, Meadows KL, Hatch AJ, Jia J, Nixon AB, Uronis HE, Morse MA, Selim MA, Crawford J, Riedel RF, Zafar SY, Howard LA, O'Neill M, Meadows JJ, Haley ST, Arrowood CC, Rushing C, Pang H, Hurwitz HI.

Oncologist. 2018 Jul;23(7):782-790. doi: 10.1634/theoncologist.2016-0377. Epub 2018 Mar 23.

10.

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.

Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, D'Angelo S, Attia S, Riedel RF, Priebat DA, Movva S, Davis LE, Okuno SH, Reed DR, Crowley J, Butterfield LH, Salazar R, Rodriguez-Canales J, Lazar AJ, Wistuba II, Baker LH, Maki RG, Reinke D, Patel S.

Lancet Oncol. 2017 Nov;18(11):1493-1501. doi: 10.1016/S1470-2045(17)30624-1. Epub 2017 Oct 4. Erratum in: Lancet Oncol. 2017 Dec;18(12 ):e711. Erratum in: Lancet Oncol. 2018 Jan;19(1):e8.

PMID:
28988646
11.

Improvements in Patient and Health System Outcomes Using an Integrated Oncology and Palliative Medicine Approach on a Solid Tumor Inpatient Service.

Riedel RF, Slusser K, Power S, Jones CA, LeBlanc TW, Kamal AH, Desai D, Allen D, Yu Y, Wolf S, Galanos AN.

J Oncol Pract. 2017 Sep;13(9):e738-e748. doi: 10.1200/JOP.2017.022749. Epub 2017 Aug 10.

PMID:
28796559
12.

Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial.

Tap WD, Papai Z, Van Tine BA, Attia S, Ganjoo KN, Jones RL, Schuetze S, Reed D, Chawla SP, Riedel RF, Krarup-Hansen A, Toulmonde M, Ray-Coquard I, Hohenberger P, Grignani G, Cranmer LD, Okuno S, Agulnik M, Read W, Ryan CW, Alcindor T, Del Muro XFG, Budd GT, Tawbi H, Pearce T, Kroll S, Reinke DK, Schöffski P.

Lancet Oncol. 2017 Aug;18(8):1089-1103. doi: 10.1016/S1470-2045(17)30381-9. Epub 2017 Jun 23. Erratum in: Lancet Oncol. 2018 Feb;19(2):e78.

PMID:
28651927
13.

Phase I study of pazopanib plus TH-302 in advanced solid tumors.

Riedel RF, Meadows KL, Lee PH, Morse MA, Uronis HE, Blobe GC, George DJ, Crawford J, Niedzwiecki D, Rushing CN, Arrowood CC, Hurwitz HI.

Cancer Chemother Pharmacol. 2017 Mar;79(3):611-619. doi: 10.1007/s00280-017-3256-2. Epub 2017 Feb 25.

PMID:
28238078
14.

Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.

von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Conrad EU 3rd, Ganjoo KN, George S, Gonzalez RJ, Heslin MJ, Kane JM 3rd, Koon H, Mayerson J, McCarter M, McGarry SV, Meyer C, O'Donnell RJ, Pappo AS, Paz IB, Petersen IA, Pfeifer JD, Riedel RF, Schuetze S, Schupak KD, Schwartz HS, Tap WD, Wayne JD, Bergman MA, Scavone J.

J Natl Compr Canc Netw. 2016 Jun;14(6):758-86.

PMID:
27283169
15.

Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour.

Wagner AJ, Agulnik M, Heinrich MC, Mahadevan D, Riedel RF, von Mehren M, Trent J, Demetri GD, Corless CL, Yule M, Lyons JF, Oganesian A, Keer H.

Eur J Cancer. 2016 Jul;61:94-101. doi: 10.1016/j.ejca.2016.03.076. Epub 2016 May 5.

16.

A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer.

Whitley MJ, Cardona DM, Lazarides AL, Spasojevic I, Ferrer JM, Cahill J, Lee CL, Snuderl M, Blazer DG 3rd, Hwang ES, Greenup RA, Mosca PJ, Mito JK, Cuneo KC, Larrier NA, O'Reilly EK, Riedel RF, Eward WC, Strasfeld DB, Fukumura D, Jain RK, Lee WD, Griffith LG, Bawendi MG, Kirsch DG, Brigman BE.

Sci Transl Med. 2016 Jan 6;8(320):320ra4. doi: 10.1126/scitranslmed.aad0293.

17.

Effects of enhanced caregiver training program on cancer caregiver's self-efficacy, preparedness, and psychological well-being.

Hendrix CC, Bailey DE Jr, Steinhauser KE, Olsen MK, Stechuchak KM, Lowman SG, Schwartz AJ, Riedel RF, Keefe FJ, Porter LS, Tulsky JA.

Support Care Cancer. 2016 Jan;24(1):327-336. doi: 10.1007/s00520-015-2797-3. Epub 2015 Jun 12.

18.

Rhabdomyosarcomatous Transformation of a Gastrointestinal Stromal Tumor following Treatment with Imatinib.

Jiang X, Anderson HB, Guy CD, Mosca PJ, Riedel RF, Cardona DM.

Case Rep Oncol Med. 2015;2015:317493. doi: 10.1155/2015/317493. Epub 2015 Jan 28.

19.

Chemotherapy in soft-tissue sarcoma: where do we go from here?

Gwin W, Riedel RF.

Oncology (Williston Park). 2015 Jan;29(1):50, 52-3. No abstract available.

20.

Gastrointestinal stromal tumors, version 2.2014.

von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Casper ES, Conrad EU 3rd, DeLaney TF, Ganjoo KN, George S, Gonzalez RJ, Heslin MJ, Kane JM 3rd, Mayerson J, McGarry SV, Meyer C, O'Donnell RJ, Pappo AS, Paz IB, Pfeifer JD, Riedel RF, Schuetze S, Schupak KD, Schwartz HS, Van Tine BA, Wayne JD, Bergman MA, Sundar H.

J Natl Compr Canc Netw. 2014 Jun;12(6):853-62.

PMID:
24925196
21.

Soft tissue sarcoma, version 2.2014.

von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Casper ES, Conrad EU 3rd, Delaney TF, Ganjoo KN, George S, Gonzalez RJ, Heslin MJ, Kane JM 3rd, Mayerson J, McGarry SV, Meyer C, O'Donnell RJ, Pappo AS, Paz IB, Pfeifer JD, Riedel RF, Schuetze S, Schupak KD, Schwartz HS, Van Tine BA, Wayne JD, Bergman MA, Sundar H; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2014 Apr;12(4):473-83.

PMID:
24717567
22.

Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.

Demetri GD, Chawla SP, Ray-Coquard I, Le Cesne A, Staddon AP, Milhem MM, Penel N, Riedel RF, Bui-Nguyen B, Cranmer LD, Reichardt P, Bompas E, Alcindor T, Rushing D, Song Y, Lee RM, Ebbinghaus S, Eid JE, Loewy JW, Haluska FG, Dodion PF, Blay JY.

J Clin Oncol. 2013 Jul 1;31(19):2485-92. doi: 10.1200/JCO.2012.45.5766. Epub 2013 May 28.

PMID:
23715582
23.

Practical radiation oncology for extremity sarcomas.

Larrier NA, Kirsch DG, Riedel RF, Levinson H, Eward WC, Brigman BE.

Surg Oncol Clin N Am. 2013 Jul;22(3):433-43. doi: 10.1016/j.soc.2013.02.004. Epub 2013 Mar 13. Review.

PMID:
23622072
24.

Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines.

von Mehren M, Benjamin RS, Bui MM, Casper ES, Conrad EU 3rd, DeLaney TF, Ganjoo KN, George S, Gonzalez R, Heslin MJ, Kane JM 3rd, Mayerson J, McGarry SV, Meyer C, O'Donnell RJ, Paz B, Pfeifer JD, Pollock RE, Randall RL, Riedel RF, Schuetze S, Schupak KD, Schwartz HS, Shankar S, Van Tine BA, Wayne J, Sundar H, McMillian NR.

J Natl Compr Canc Netw. 2012 Aug;10(8):951-60.

PMID:
22878820
25.

Pathologic complete response of a malignant peripheral nerve sheath tumor in the lung treated with neoadjuvant Ifosfamide and radiation therapy.

Cuneo KC, Riedel RF, Dodd LG, Harpole DH Jr, Kirsch DG.

J Clin Oncol. 2012 Oct 1;30(28):e291-3. Epub 2012 Aug 6. No abstract available.

26.

A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors.

Vlahovic G, Meadows KL, Uronis HE, Morse MA, Blobe GC, Riedel RF, Zafar SY, Alvarez-Secord A, Gockerman J, Starodub AN, Ready NE, Anderson EL, Bendell JC, Hurwitz HI.

Cancer Chemother Pharmacol. 2012 Jul;70(1):95-102. doi: 10.1007/s00280-012-1889-8. Epub 2012 May 26.

27.

Efficacy of phosphatidylinositol-3 kinase inhibitors in a primary mouse model of undifferentiated pleomorphic sarcoma.

Kim S, Dodd RD, Mito JK, Ma Y, Kim Y, Riedel RF, Kirsch DG.

Sarcoma. 2012;2012:680708. doi: 10.1155/2012/680708. Epub 2012 Apr 29.

28.

Retraction in part: A genomic approach to identify molecular pathways associated with chemotherapy resistance.

Riedel RF, Porrello A, Pontzer E, Chenette EJ, Hsu DS, Balakumaran B, Potti A, Nevins J, Febbo PC.

Mol Cancer Ther. 2012 May;11(5):1214-5. doi: 10.1158/1535-7163.MCT-12-0210. Epub 2012 Mar 29. No abstract available.

29.

Targeted therapy in sarcoma: should we be lumpers or splitters?

Riedel RF, Maki RG, Wagner AJ.

Am Soc Clin Oncol Educ Book. 2012:652-7. doi: 10.14694/EdBook_AM.2012.32.652.

PMID:
24451813
30.

Targeted agents for sarcoma: is individualized therapy possible in such a diverse tumor type?

Riedel RF.

Semin Oncol. 2011 Oct;38 Suppl 3:S30-42. doi: 10.1053/j.seminoncol.2011.09.003. Review.

PMID:
22055970
31.

Systemic therapy for advanced soft tissue sarcomas: highlighting novel therapies and treatment approaches.

Riedel RF.

Cancer. 2012 Mar 15;118(6):1474-85. doi: 10.1002/cncr.26415. Epub 2011 Aug 11. Review.

32.

Primary meningeal rhabdomyosarcoma.

Palta M, Riedel RF, Vredenburgh JJ, Cummings TJ, Green S, Chang Z, Kirkpatrick JP.

Sarcoma. 2011;2011:312802. doi: 10.1155/2011/312802. Epub 2011 Jun 23.

33.

Emerging therapeutic targets for soft tissue sarcoma.

Smith JL, Riedel RF.

Curr Oncol Rep. 2011 Aug;13(4):350-8. doi: 10.1007/s11912-011-0175-y. Review.

PMID:
21523334
34.

Retraction: Genomic signatures to guide the use of chemotherapeutics.

Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, Cragun J, Cottrill H, Kelley MJ, Petersen R, Harpole D, Marks J, Berchuck A, Ginsburg GS, Febbo P, Lancaster J, Nevins JR.

Nat Med. 2011 Jan;17(1):135. doi: 10.1038/nm0111-135. No abstract available.

PMID:
21217686
35.

Soft tissue sarcoma.

Demetri GD, Antonia S, Benjamin RS, Bui MM, Casper ES, Conrad EU 3rd, DeLaney TF, Ganjoo KN, Heslin MJ, Hutchinson RJ, Kane JM 3rd, Letson GD, McGarry SV, O'Donnell RJ, Paz IB, Pfeifer JD, Pollock RE, Randall RL, Riedel RF, Schupak KD, Schwartz HS, Thornton K, von Mehren M, Wayne J; National Comprehensive Cancer Network Soft Tissue Sarcoma Panel.

J Natl Compr Canc Netw. 2010 Jun;8(6):630-74. No abstract available.

PMID:
20581298
36.

NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.

Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, Pisters PW, Raut CP, Riedel RF, Schuetze S, Sundar HM, Trent JC, Wayne JD.

J Natl Compr Canc Netw. 2010 Apr;8 Suppl 2:S1-41; quiz S42-4.

37.

Cross species genomic analysis identifies a mouse model as undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma.

Mito JK, Riedel RF, Dodd L, Lahat G, Lazar AJ, Dodd RD, Stangenberg L, Eward WC, Hornicek FJ, Yoon SS, Brigman BE, Jacks T, Lev D, Mukherjee S, Kirsch DG.

PLoS One. 2009 Nov 30;4(11):e8075. doi: 10.1371/journal.pone.0008075.

38.

Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer.

Hsu DS, Acharya CR, Balakumaran BS, Riedel RF, Kim MK, Stevenson M, Tuchman S, Mukherjee S, Barry W, Dressman HK, Nevins JR, Powers S, Mu D, Potti A.

Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5312-7. doi: 10.1073/pnas.0900827106. Epub 2009 Mar 11. Erratum in: Proc Natl Acad Sci U S A. 2011 Aug 30;108(35):14705.

39.

The clinical management of chondrosarcoma.

Riedel RF, Larrier N, Dodd L, Kirsch D, Martinez S, Brigman BE.

Curr Treat Options Oncol. 2009 Apr;10(1-2):94-106. doi: 10.1007/s11864-009-0088-2. Epub 2009 Feb 24. Review.

PMID:
19238552
40.

A genomic approach to identify molecular pathways associated with chemotherapy resistance.

Riedel RF, Porrello A, Pontzer E, Chenette EJ, Hsu DS, Balakumaran B, Potti A, Nevins J, Febbo PG.

Mol Cancer Ther. 2008 Oct;7(10):3141-9. doi: 10.1158/1535-7163.MCT-08-0642. Erratum in: Mol Cancer Ther. 2012 May;11(5):1214-5.

41.

Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer.

Hsu DS, Balakumaran BS, Acharya CR, Vlahovic V, Walters KS, Garman K, Anders C, Riedel RF, Lancaster J, Harpole D, Dressman HK, Nevins JR, Febbo PG, Potti A.

J Clin Oncol. 2007 Oct 1;25(28):4350-7. Erratum in: J Clin Oncol. 2010 Jun 1;28(16):2805. Retraction in: J Clin Oncol. 2010 Dec 10;28(35):5229.

PMID:
17906199
42.

A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer.

Riedel RF, Andrews C, Garst J, Dunphy F, Herndon JE 2nd, Blackwell S, Barbour S, Crawford J.

J Thorac Oncol. 2007 Jun;2(6):520-5.

43.

Impact of a multidisciplinary thoracic oncology clinic on the timeliness of care.

Riedel RF, Wang X, McCormack M, Toloza E, Montana GS, Schreiber G, Kelley MJ.

J Thorac Oncol. 2006 Sep;1(7):692-6.

44.

Genomic signatures to guide the use of chemotherapeutics.

Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, Cragun J, Cottrill H, Kelley MJ, Petersen R, Harpole D, Marks J, Berchuck A, Ginsburg GS, Febbo P, Lancaster J, Nevins JR.

Nat Med. 2006 Nov;12(11):1294-300. Epub 2006 Oct 22. Erratum in: Nat Med. 2007 Nov;13(11):1388. Nat Med. 2008 Aug;14(8):889. Retraction in: Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, Cragun J, Cottrill H, Kelley MJ, Petersen R, Harpole D, Marks J, Berchuck A, Ginsburg GS, Febbo P, Lancaster J, Nevins JR. Nat Med. 2011 Jan;17(1):135.

PMID:
17057710
45.

Phase II study of carboplatin, irinotecan, and thalidomide combination in patients with extensive stage small-cell lung cancer.

Riedel RF, Crawford J, Dunphy F, Herndon JE 2nd, Garst J, Kelley MJ.

Lung Cancer. 2006 Dec;54(3):431-2. Epub 2006 Sep 26. No abstract available.

PMID:
17005294
46.

Thymoma: benign appearance, malignant potential.

Riedel RF, Burfeind WR Jr.

Oncologist. 2006 Sep;11(8):887-94.

47.
48.

Small-cell lung cancer: a review of clinical trials.

Riedel RF, Crawford J.

Semin Thorac Cardiovasc Surg. 2003 Oct;15(4):448-56. Review.

PMID:
14710387
49.

Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development.

Luetteke NC, Qiu TH, Fenton SE, Troyer KL, Riedel RF, Chang A, Lee DC.

Development. 1999 Jun;126(12):2739-50.

50.

Expression of constitutively active Raf-1 in the mitochondria restores antiapoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant.

Salomoni P, Wasik MA, Riedel RF, Reiss K, Choi JK, Skorski T, Calabretta B.

J Exp Med. 1998 Jun 15;187(12):1995-2007.

Supplemental Content

Loading ...
Support Center